Notable in Neurology
This issue features an article investigating the SQSTM1 splice site mutation in distal myopathy with rimmed vacuoles and another on PET imaging results of amyloid-b 11 C-Pittsburgh compound B from 2 randomized bapineuzumab phase 3 Alzheimer disease trials. Another featured article focuses on migraine and the risk of stroke in older adults.
ARTICLES

Rapid progression of familial amyloidotic polyneuropathy: A multinational natural history study
This study offers a worldwide perspective on familial amyloidotic polyneuropathy-its natural history, severity, and progression. In a population of 283 patients, there was an intercountry genotypic variation in the transthyretin mutation with an association between Neuropathy Impairment Scores, locomotion grip strength, and transthyretin genotype, with a rapid yearly neuropathic progression.
See p. 675
Standard chemoradiation for glioblastoma results in progressive brain volume loss Understanding cancer therapy-associated neurotoxic adverse events is an important issue in oncology, and defining novel biomarkers of neurotoxicity is essential for developing neuroprotective strategies. Using longitudinal neuroimaging, the investigators identified progressive gray matter loss and expansion of ventricular volume in patients with glioblastoma treated with standard chemotherapy and fractionated brain irradiation.
See p. 683; Comment, p. 689
Statin treatment reduces the risk of poststroke seizures Multivariable regression analyses were used to assess the relationship between statin use and poststroke seizures. This study showed that in patients with stroke, the early use of statins may reduce the risk of poststroke early-onset seizures and prevent the progression of initial poststroke seizures to chronic epilepsy.
See p. 701
From editorialists Siniscalchi & Mintzer: ".data obtained from this study support the use of statins in poststroke patients for reducing the risk of acute seizures, especially for preventing chronic epilepsy in those who have had an acute seizure."
See p. 661
Response to endovascular reperfusion is not time-dependent in patients with salvageable tissue
